We are a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases.

Our discovery and development programs are driven by unmet medical and patient needs and strong science supported by our two patented transgenic mouse platforms for generating fully human monoclonal antibodies. We focus on developing an innovative pipeline of Next-Gen therapeutics through our internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.

With operations in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Shanghai/Suzhou, China, we also license our core platform technology to other companies and academic institutions globally.
友情链接:香港六合论坛开奖|首页  澳门银河公司  ag88环亚国际厅  sbf888胜博发  申博138网app下载  澳门皇冠投注  巴黎人平台  下载app送28彩金